Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. It is crucial for clinicians to exercise independent medical judgment, consult relevant guidelines, and make patient care decisions based on the individual clinical context. This content does not replace the need for direct patient evaluation or consultation with specialists.

Maxillectomy Classification

Overview

• Definition: Maxillectomy refers to the surgical resection of part or all of the maxilla (upper jaw bone). This procedure is primarily performed for the surgical management of malignant and, less commonly, benign tumors involving the maxilla, paranasal sinuses, nasal cavity, and adjacent structures. The extent of resection is highly variable and depends on the tumor's size, location, and invasion into surrounding tissues.
• Epidemiology: Maxillectomies are most frequently indicated for malignancies originating in or invading the maxillary sinus. Malignant tumors of the maxillary sinus are rare, accounting for approximately 0.2-1.2% of all malignancies and 3% of head and neck cancers. Squamous cell carcinoma (SCC) is the most common histological type, comprising 70-80% of cases, followed by adenocarcinoma, adenoid cystic carcinoma, melanoma, and sarcomas. Incidence peaks in the 5th to 7th decades of life, with a male predominance. The specific epidemiology relates to the underlying pathology necessitating the maxillectomy.
• Classification: The classification of maxillectomy is crucial for surgical planning, predicting functional and aesthetic outcomes, guiding reconstruction, and standardizing communication among clinicians. The most widely accepted and clinically relevant classification system is the Brown Classification (developed by JS Brown et al.), which categorizes maxillectomies based on the extent of bone and soft tissue resection, particularly regarding orbital involvement.

Brown Classification of Maxillectomy Defects:

This classification system details the extent of maxillectomy and often implies the complexity of the resulting defect and reconstructive needs.

• Type I: Infraorbital Maxillectomy

  • Resection limited to the hard palate and alveolar bone below the infraorbital rim.
  • Preserves the orbital floor, zygoma, and infraorbital rim.
  • Often involves removal of the medial wall of the maxillary sinus.
  • Results in a defect confined to the hard palate and alveolus.

• Type II: Subtotal Maxillectomy

  • Resection includes the infraorbital rim and/or orbital floor, often extending to the medial orbital wall.
  • Preserves the lateral orbital wall and zygoma.
  • May involve removal of the inferior turbinate and part of the nasal septum.
  • Results in a defect involving the hard palate, alveolus, and portions of the orbital floor.

• Type III: Total Maxillectomy

  • Resection of the entire maxilla on one side, including the hard palate, alveolar bone, zygoma, and complete orbital floor.
  • The orbital contents may or may not be preserved (subdivided as Type IIIA or IIIB).
  • Type IIIA: Total maxillectomy with preservation of the orbital contents.
  • Type IIIB: Total maxillectomy with orbital exenteration (removal of orbital contents).

• Type IV: Radical Maxillectomy

  • Resection involves the entire maxilla on one side along with orbital exenteration.
  • The tumor has invaded the orbital contents, necessitating enucleation or exenteration.
  • Equivalent to a Type IIIB in some systems but explicitly emphasizes orbital exenteration as a defining feature.

• Type V: Craniofacial Resection (Skull Base Maxillectomy)

  • Resection extends beyond the maxilla to involve the skull base (e.g., ethmoid, sphenoid, frontal bones).
  • This is typically a combined neurosurgical and head & neck surgical approach.
  • Subdivided based on the extent of skull base involvement (e.g., anterior, middle cranial fossa).

Additional Considerations/Other Classifications: * Partial vs. Total: A simpler, less detailed classification where partial indicates removal of a segment, and total indicates removal of the entire bone. * Weber-Ferguson Incision based Classification: Historically, descriptions of maxillectomy were often tied to the specific surgical incision used (e.g., modified Weber-Ferguson for total maxillectomy), but this describes access, not the defect. * Reconstructive Classification: Some systems implicitly or explicitly link the maxillectomy type to the required reconstructive strategy (e.g., obturator prosthesis, local flaps, regional flaps, free tissue transfer). The Brown classification inherently guides this.

Pathophysiology

• Mechanism: The need for maxillectomy typically arises from the growth and local invasion of malignant tumors originating in the paranasal sinuses, nasal cavity, or adjacent structures like the oral cavity or orbit. These tumors erode through bone (e.g., maxilla, palate, orbital floor) and infiltrate soft tissues. The extent of the maxillectomy is dictated by the tumor's pathological spread, aiming for complete oncological resection with clear margins while preserving function and aesthetics as much as possible.
• Risk Factors: (For the underlying malignancies necessitating maxillectomy)
  • Tobacco Use: Cigarette, cigar, pipe smoking, and smokeless tobacco are major risk factors for squamous cell carcinoma.
  • Alcohol Consumption: Synergistic effect with tobacco for SCC.
  • Occupational Exposures: Chronic exposure to certain industrial agents (e.g., wood dust, nickel, chromium, leather dust, textile dust, formaldehyde, isopropyl alcohol) is linked to sinonasal adenocarcinomas and SCC.
  • Chronic Sinusitis/Inflammation: Unresolved chronic inflammation may rarely predispose to malignancy.
  • Human Papillomavirus (HPV): High-risk HPV types (e.g., HPV-16) are increasingly implicated in a subset of sinonasal SCCs, similar to oropharyngeal SCC.
  • Epstein-Barr Virus (EBV): Associated with nasopharyngeal carcinoma, which can invade the maxilla.
  • Prior Radiation Exposure: History of therapeutic radiation to the head and neck region for other malignancies.
  • Genetic Predisposition: Rare familial syndromes or genetic mutations.
• Protective Factors: (For preventing the underlying malignancies)
  • Cessation of tobacco use and avoidance of passive smoke exposure.
  • Moderation or abstinence from alcohol consumption.
  • Adherence to occupational safety measures (e.g., use of personal protective equipment in high-risk industries).
  • HPV vaccination (primarily targeting oropharyngeal cancers, but potential broader impact on head and neck SCCs).
  • Healthy diet rich in fruits and vegetables.

Clinical Presentation

Signs and Symptoms

Clinical presentation depends on the tumor's origin, size, and extent of invasion. Early signs are often subtle and non-specific, leading to delayed diagnosis. - Cardinal Features: * Facial Swelling/Asymmetry: Unilateral cheek swelling, proptosis (bulging eye), or upward displacement of the eyeball. * Nasal Obstruction: Unilateral, progressive nasal blockage, often with discharge. * Pain: Facial pain, headache, orbital pain, or toothache (often unresponsive to dental treatment). * Epistaxis: Recurrent or persistent nosebleeds, especially unilateral. * Oral Symptoms: Ill-fitting dentures, loose teeth, swelling of the hard palate or alveolar ridge, numbness of the upper lip or cheek (due to infraorbital nerve involvement). - Early Signs: * Unilateral nasal stuffiness or discharge (mucopurulent or blood-tinged). * Mild facial discomfort or pressure. * Minor epistaxis. * Subtle changes in vision or diplopia. - Advanced Signs: * Severe facial deformity, visible masses. * Proptosis, ophthalmoplegia (restricted eye movement), vision loss, or blindness. * Anesthesia or paresthesia in the V2 distribution (cheek, upper lip, ala of nose, upper teeth). * Trismus (difficulty opening mouth) due to pterygoid muscle involvement. * Cranial nerve palsies (e.g., CN V, VII, IX, X, XI, XII if skull base involvement). * Orbital pain, tearing (epiphora). * Oral fistula or ulceration of the palate. * Lymphadenopathy (cervical metastases). * Systemic symptoms: Weight loss, fatigue, malaise. - Atypical Presentations: * Mimicking chronic sinusitis or dental infections. * Nerve pain mimicking trigeminal neuralgia. * Isolated proptosis without other obvious sinonasal symptoms.

Physical Examination

• Inspection:
  • Facial asymmetry, swelling of the cheek or orbit.
  • Proptosis, displacement of the globe.
  • Skin changes (erythema, ulceration).
  • Intraoral: Swelling, ulceration, or mass on the hard palate, alveolar ridge, or gingiva. Unilateral loosening of teeth.
  • Nasal: Nasal discharge, masses visible on anterior rhinoscopy.
• Palpation:
  • Palpable mass in the cheek or palate.
  • Tenderness over the maxillary sinus.
  • Crepitus if bony erosion.
  • Assessment of cervical lymph nodes for adenopathy (size, consistency, mobility).
• Special Tests:
  • Nasal Endoscopy: Crucial for direct visualization of the nasal cavity and nasopharynx, identifying masses, bleeding, or purulent discharge. Allows for targeted biopsies.
  • Ophthalmologic Examination: Assessment of visual acuity, extraocular movements, presence of proptosis, and fundoscopy if orbital involvement is suspected.
  • Neurological Examination: Especially focusing on cranial nerves (V2 sensation, ocular motility) to detect perineural or skull base invasion.

Diagnostic Approach

History Taking

• Key Questions:
  • Duration and progression of symptoms (nasal obstruction, discharge, epistaxis, facial pain/swelling, vision changes, oral symptoms).
  • Presence of risk factors (smoking, alcohol, occupational exposures, prior radiation).
  • Systemic symptoms (weight loss, fatigue, fever).
  • Any history of chronic sinusitis or nasal polyps.
  • Previous medical/surgical history.
• Red Flags:
  • Unilateral, persistent, or progressive symptoms (nasal obstruction, epistaxis, facial swelling).
  • New-onset facial numbness or pain in the V2 distribution.
  • Rapidly progressive proptosis or vision changes.
  • Unexplained loosening of teeth or ill-fitting dentures.
  • Palpable hard mass in the cheek or palate.
  • Cervical lymphadenopathy.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): To assess overall health, detect anemia (due to chronic bleeding), or infection.
  • Basic Metabolic Panel (BMP): Renal and electrolyte status for surgical planning.
  • Liver Function Tests (LFTs): To assess liver function and screen for metastatic disease.
  • Coagulation Profile (PT/INR, PTT): Essential pre-operatively for surgical candidates.
• Confirmatory:
  • Biopsy (Incisional or Endoscopic): The definitive diagnostic test for malignancy. Obtained from the primary tumor site (nasal cavity, maxillary sinus via endoscopic approach, or intraoral). Histopathological examination and immunohistochemistry are critical for diagnosis and subtyping.
• Monitoring:
  • Post-operatively: CBC (for anemia, infection), BMP.
  • Long-term: No specific lab markers for recurrence, but tumor markers may be followed for certain specific histologies (e.g., CEA for adenocarcinoma, S-100 for melanoma, though less common for primary sinonasal tumors).

Imaging

• Recommended:
  • Computed Tomography (CT) Scan with Contrast of Paranasal Sinuses and Facial Bones: First-line imaging. Provides excellent bony detail, delineates tumor extent, erosion of bony walls (maxilla, orbital floor, skull base), and involvement of adjacent sinuses. Crucial for surgical planning and classification of maxillectomy.
    • Specifics: Thin cuts (e.g., 1 mm) with multiplanar reconstructions (axial, coronal, sagittal). Bone and soft tissue windows.
  • Magnetic Resonance Imaging (MRI) with Contrast of Head and Neck: Complementary to CT. Superior for soft tissue differentiation, perineural spread, dural invasion, intracranial extension, and orbital involvement.
    • Sequences: T1-weighted pre- and post-contrast, T2-weighted, DWI (diffusion-weighted imaging).
  • Chest CT: For metastatic work-up, as lung is a common site for distant metastasis in head and neck cancers.
• Advanced:
  • Positron Emission Tomography-CT (PET-CT) Scan: For detecting regional nodal metastases and distant metastatic disease, especially in advanced-stage tumors or for re-staging. Not routinely used for early-stage disease but helpful in initial staging of advanced disease or detecting occult primary/recurrence.
  • Angiography (with embolization): Rarely used diagnostically, but may be performed pre-operatively for highly vascular tumors (e.g., angiofibromas, some sarcomas) to reduce intraoperative bleeding.

Management

Maxillectomy classification directly impacts surgical planning and the reconstructive strategy. The overarching management strategy is multimodal for most malignant tumors.

Acute Management

• Immediate:
  • Airway Assessment and Management: If severe nasal obstruction or trismus threatens the airway, secure airway via nasopharyngeal airway, orotracheal intubation, or emergent tracheostomy.
  • Bleeding Control: For significant epistaxis from tumor, local packing or embolization may be required.
  • Pain Control: Analgesics as needed.
• Stabilization:
  • Complete diagnostic workup including staging.
  • Optimization of comorbidities (e.g., diabetes, hypertension, cardiac disease).
  • Nutritional assessment and support, as many patients are malnourished.
• Emergency:
  • Massive hemorrhage (rare, but can occur with highly vascular tumors).
  • Orbital compartment syndrome (due to tumor or inflammation), requiring urgent decompression.
  • Acute intracranial complications (e.g., severe skull base erosion with CSF leak or meningitis, rare before surgery).

Chronic Management

• Pharmacological:
  • Adjuvant Therapy: Depending on tumor type, stage, and pathological findings (positive margins, perineural invasion, lymphovascular invasion, extracapsular spread), post-operative radiotherapy, chemoradiotherapy, or chemotherapy may be indicated.
    • Radiotherapy: Typically 60-70 Gy over 6-7 weeks, often for positive margins, T3/T4 tumors, N+ disease, or high-risk features.
    • Chemoradiotherapy: Concurrent cisplatin-based chemotherapy (e.g., Cisplatin 100 mg/m2 IV q3 weeks for 3 cycles) with radiation for high-risk SCCs.
    • Targeted Therapy/Immunotherapy: Emerging role for specific tumor types (e.g., pembrolizumab for recurrent/metastatic SCC, specific mutations).
  • Analgesia: For chronic pain post-operatively or from recurrence.
  • Antibiotics: For infections (e.g., sinusitis, wound infection, osteomyelitis).
• Non-pharmacological:
  • Reconstruction: Essential for restoring function (mastication, speech, swallowing, vision) and aesthetics. The Brown classification guides the choice:
    • Type I: Often managed with an obturator prosthesis (dental restoration to seal oral-antral communication) or local flaps (e.g., palatal flaps, buccal fat pad).
    • Type II: May require larger obturator prostheses, regional flaps (e.g., temporalis flap, pectoralis major flap), or free flaps (e.g., radial forearm free flap, anterolateral thigh free flap).
    • Type III/IV/V: Almost always require complex microvascular free tissue transfer (e.g., fibula free flap for bony reconstruction, rectus abdominis or anterolateral thigh for soft tissue bulk) to reconstruct the orbital floor, midface contour, and often create a new lining. Obturator prosthesis may still be used in conjunction.
  • Speech and Swallowing Therapy: Rehabilitation to address deficits post-operatively.
  • Ocular Prosthesis/Eyeglasses: If orbital exenteration performed.
  • Psychological Support: To cope with disfigurement, functional loss, and cancer diagnosis.
  • Nutrition: Dietary counseling, possible PEG tube for severe dysphagia.
• Monitoring:
  • Post-operative Surveillance: Regular follow-up with physical exams (oral cavity, nasal cavity, neck), imaging (CT/MRI) at intervals (e.g., every 3 months for first year, then 6 months for 2-3 years, then annually).
  • Dental Surveillance: Regular checks for obturator fit and dental health.

Treatment Algorithms

Treatment for maxillary tumors is highly individualized based on stage, histology, patient comorbidities, and surgeon expertise. Maxillectomy is typically the cornerstone of treatment for resectable disease.

• First-Line:
  • Resectable Disease (T1-T4a N0/N+ M0): Primary surgical resection (maxillectomy based on tumor extent) with clear margins.
    • Followed by: Adjuvant radiotherapy or chemoradiotherapy based on pathological high-risk features (positive margins, PNI, LVI, multiple N+, ENE).
• Second-Line:
  • Unresectable Disease (T4b or M1): Primary chemoradiotherapy or palliative systemic therapy (chemotherapy, immunotherapy, targeted therapy). Surgery may be considered for salvage in select cases after definitive non-surgical treatment fails.
  • Recurrent Disease: Depends on previous treatment and site of recurrence. May involve salvage surgery (more extensive maxillectomy or skull base resection), re-irradiation (complex, high toxicity), or systemic therapy.
• Refractory Cases:
  • Management often palliative, focusing on symptom control, pain management, nutritional support, and quality of life. Clinical trials may be an option.

Complications

Complications vary significantly with the extent of maxillectomy (classification type) and reconstructive method. - Common: * Pain and Swelling: Post-operative. * Infection: Wound infection, osteomyelitis. * Trismus: Due to scar contracture or pterygoid muscle involvement. * Epiphora: Due to nasolacrimal duct obstruction. * Oro-antral/oro-nasal fistula: Communication between oral cavity and sinus/nasal cavity, especially with obturator use or flap failure. Leads to leakage of food/liquid into nasal cavity. * Dental complications: Malocclusion, difficulty with dentures. - Serious: * Hemorrhage: Intra- or post-operative. * CSF Leak: If skull base is involved (Type V maxillectomy). Risk is 5-10% in craniofacial resections. * Vision Loss/Diplopia: Due to orbital floor collapse, damage to ocular muscles, or optic nerve injury. More common with Type II, III, IV maxillectomies. * Cranial Nerve Injuries: Especially infraorbital nerve (sensory deficit), facial nerve (rare, if parotid involved), or lower cranial nerves with skull base extension. * Brain Injury/Meningitis: Extremely rare, associated with Type V. * Reconstructive Flap Failure: Leading to wound breakdown, infection, exposure of vital structures, requiring revision surgery. * Syndrome of Inappropriate Antidiuretic Hormone (SIADH): Can occur post-operatively, especially with skull base surgery. - Long-term: * Facial Deformity and Disfigurement: Significant aesthetic impact, even with optimal reconstruction. * Speech and Swallowing Difficulties: Persistent dysphagia and dysarthria. * Chronic Sinusitis: Due to altered anatomy and impaired mucociliary clearance. * Dental Issues: Need for long-term prosthetic rehabilitation. * Psychological Distress: Depression, anxiety, social isolation due to altered appearance and function. * Recurrence of Cancer: Local, regional, or distant. * Secondary Malignancies: Especially in patients with ongoing risk factors (e.g., smoking).

Prognosis

Prognosis for patients undergoing maxillectomy is primarily determined by the underlying malignancy. - Factors: * Tumor Stage (TNM): Most important prognostic factor. Smaller tumors (T1/T2) confined to the maxilla have a better prognosis than large, invasive tumors (T3/T4) with orbital, skull base, or extensive soft tissue involvement. * Lymph Node Involvement (N-status): Presence of regional metastases significantly worsens prognosis. Extracapsular spread is a particularly poor prognostic indicator. * Distant Metastasis (M-status): Presence of distant metastasis (e.g., lung, bone, liver) indicates Stage IVc disease and is associated with very poor prognosis. * Histological Type: Adenoid cystic carcinoma (slow-growing but high recurrence and distant metastasis rate), melanoma (aggressive), sarcomas (variable). SCC prognosis depends on differentiation and features. * Surgical Margins: Positive surgical margins are associated with significantly higher rates of local recurrence and worse survival. * Perineural Invasion (PNI) and Lymphovascular Invasion (LVI): Both are adverse pathological features. * Patient Performance Status and Comorbidities: Impact ability to tolerate aggressive treatment and recover. * Adjuvant Therapy: Appropriate post-operative treatment (radiation, chemotherapy) can improve outcomes for high-risk patients. - Survival: * Overall 5-year survival rates for maxillary sinus cancers vary widely based on stage and histology, ranging from 30-60%. * Early stage (T1/T2 N0 M0): 5-year survival rates can exceed 70-80%. * Advanced stage (T4 N+ M0): 5-year survival rates drop to 20-40%. * Distant metastasis (M1): Prognosis is grim, often <10% 5-year survival. - Quality of Life: * Maxillectomy, especially more extensive types (II, III, IV, V), significantly impacts quality of life due to functional deficits (speech, swallowing, vision, chewing) and aesthetic disfigurement. * Reconstruction plays a critical role in mitigating these impacts. Functional and aesthetic outcomes are better with free flap reconstruction compared to obturator alone for large defects. * Psychosocial well-being is often compromised and requires ongoing support.

Prevention

Prevention is primarily aimed at preventing the underlying malignancies. - Primary: * Tobacco and Alcohol Cessation: Most impactful preventive measure. Public health campaigns, counseling, and cessation programs. * Occupational Safety: Strict adherence to industrial safety regulations, use of personal protective equipment (PPE) to minimize exposure to carcinogens (e.g., wood dust, nickel). * HPV Vaccination: Particularly for younger populations, to prevent HPV-related head and neck cancers. * Healthy Lifestyle: Balanced diet, regular exercise, maintaining a healthy weight. - Secondary: * Early Detection: Awareness campaigns for early symptoms of sinonasal cancers among general practitioners and dentists. * Prompt Evaluation: Persistent or unilateral sinonasal symptoms (nasal obstruction, epistaxis, facial pain/swelling) should prompt early referral to ENT or oral maxillofacial specialists for thorough evaluation and endoscopy. * Biopsy of Suspicious Lesions: Any suspicious lesion in the oral cavity or nasal cavity warrants a biopsy. - Tertiary: * Adherence to Treatment: Ensuring compliance with post-operative adjuvant therapy (radiation, chemotherapy). * Regular Surveillance: Post-treatment follow-up to detect recurrence early and manage complications. * Rehabilitation: Timely and comprehensive speech, swallowing, and prosthetic rehabilitation to minimize long-term functional deficits and improve quality of life.

Special Populations

• Pediatric: Maxillary tumors in children are rare and often differ histologically (e.g., rhabdomyosarcoma, osteosarcoma, juvenile nasopharyngeal angiofibroma). Maxillectomy in children requires special consideration of facial growth and development. Reconstruction must account for growth potential.
• Geriatric: Elderly patients may have more comorbidities, impacting surgical candidacy and tolerance for aggressive adjuvant therapy. Assessment of functional status and goals of care is crucial. Maxillectomy may be performed, but reconstruction choices might be modified based on patient's general health, nutritional status, and ability to manage complex prostheses or undergo prolonged free flap surgery.
• Pregnancy: Diagnosis and management of maxillary tumors during pregnancy are challenging. Imaging (MRI preferred over CT to avoid radiation, or low-dose CT if essential) and treatment planning need to balance maternal and fetal well-being. Surgery may be delayed until the second trimester or after delivery if feasible and oncologically safe. Radiation and chemotherapy are generally avoided during pregnancy, especially in the first trimester.
• Comorbidities:
  • Cardiovascular/Pulmonary Disease: Increased surgical risk. Careful pre-operative optimization, possibly requiring shorter operative times or less extensive reconstruction.
  • Diabetes Mellitus: Increased risk of infection, impaired wound healing, and flap complications. Strict glycemic control is essential.
  • Renal/Hepatic Dysfunction: Impacts drug metabolism (e.g., chemotherapy agents) and fluid management.
  • Immunocompromised Patients: Higher risk of post-operative infection and poorer healing. Prophylactic antibiotics and meticulous wound care are vital.

Clinical Pearls

• Diagnostic:
  • Unilateral Symptoms are Key: Any unilateral, persistent sinonasal or oral symptom should raise suspicion for malignancy until proven otherwise, especially in patients with risk factors.
  • Biopsy is King: Imaging provides invaluable staging information, but biopsy is the only definitive diagnosis. Ensure representative tissue is obtained.
  • Multidisciplinary Approach: Pre-operative planning (tumor board) with ENT surgeon, radiation oncologist, medical oncologist, oral maxillofacial surgeon, ocular surgeon, and reconstructive surgeon is crucial for optimal outcomes.
• Treatment:
  • Oncologic Resection First: Achieving clear surgical margins is paramount, even if it means a more extensive maxillectomy (higher Brown classification). Reconstruction is secondary to oncologic clearance.
  • Reconstruction Planning is Integral: The reconstructive approach should be planned before the maxillectomy, as it often dictates aspects of the resection. The Brown classification directly facilitates this.
  • Orbital Exenteration: A difficult decision. It should only be performed if the tumor directly invades the orbital contents and cannot be cleared with globe-preserving surgery. Consider potential for vision-sparing options if tumor is extraconal.
  • Dental Assessment: Essential before surgery, as pre-existing dental disease can complicate obturator use or osteoradionecrosis risk.
• Pitfalls:
  • Misdiagnosis as Chronic Sinusitis: The most common pitfall, leading to delayed diagnosis and advanced disease presentation. Lack of response to standard sinusitis treatment should prompt further investigation.
  • Inadequate Biopsy: Superficial biopsy may miss underlying malignancy, especially in deeper tumors.
  • Underestimation of Tumor Extent: Relying solely on clinical exam; imaging is critical for defining true tumor boundaries and planning the appropriate maxillectomy type.
  • Neglecting Quality of Life: While oncologic clearance is primary, ignoring functional and aesthetic outcomes can severely impact patient's long-term well-being.
  • Failure to Address Risk Factors: Not counseling patients on tobacco and alcohol cessation increases the risk of recurrence and secondary primaries.

Recent Updates

• Guidelines:
  • NCCN Guidelines for Head and Neck Cancers: Regularly updated comprehensive guidelines provide evidence-based recommendations for diagnosis, staging, and treatment of sinonasal cancers, including indications for maxillectomy and adjuvant therapy.
  • AJCC Staging Manual (8th Edition): Updated staging criteria are crucial for accurate prognosis and treatment planning.
• Evidence:
  • Advancements in Microvascular Reconstruction: Improved free flap success rates (often >95%) due to enhanced surgical techniques, microsurgical instruments, and post-operative monitoring protocols. This has expanded the feasibility of complex reconstructions for all Brown classification types.
  • Improved Imaging Modalities: Higher resolution CT and MRI with advanced sequences (e.g., DTI, perfusion imaging) provide better pre-operative assessment of tumor invasion and perineural spread.
  • Targeted Therapies and Immunotherapy: Emerging role of agents like EGFR inhibitors, PD-1 inhibitors (e.g., pembrolizumab, nivolumab) in recurrent, metastatic, or advanced-stage squamous cell carcinomas of the head and neck, offering new treatment avenues for patients with maxillectomy defects.
  • Patient-Reported Outcomes (PROs): Growing emphasis on incorporating PROs into clinical trials and practice to better understand the patient's perspective on functional outcomes and quality of life after maxillectomy and reconstruction.
• Controversies:
  • Role of Neoadjuvant Therapy: Whether neoadjuvant chemotherapy or chemoradiotherapy improves outcomes for advanced maxillary sinus cancers prior to maxillectomy is still debated, with studies showing mixed results.
  • Mandatory Neck Dissection: For N0 maxillary sinus cancers, the necessity and extent of elective neck dissection remain controversial, with many centers advocating for observation or selective neck dissection based on T-stage and specific risk factors.
  • Orbital Preservation vs. Exenteration: The criteria for globe preservation in cases of orbital invasion remain challenging. Balancing oncologic clearance with visual function is a continuous dilemma, with ongoing research into the exact extent of orbital invasion requiring exenteration.

Key References

• Guidelines:
  • National Comprehensive Cancer Network (NCCN) Guidelines for Head and Neck Cancers. Available at: NCCN.org (Subscription/registration may be required).
  • American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th Edition.
• Studies:
  • Brown, J. S., et al. "The role of free tissue transfer in reconstruction after maxillectomy." British Journal of Plastic Surgery, 2000. (Landmark paper on Brown Classification and reconstruction).
  • Snyderman, C. H., et al. "Outcomes of endoscopic skull base surgery for primary or recurrent malignancies." Laryngoscope, 2011. (Relevant for Type V maxillectomies).
  • Myers, E. N., & Suen, J. Y. (Eds.). Cancer of the Head and Neck. Elsevier Saunders. (Comprehensive textbook covering maxillectomy and related oncologic principles).
• Reviews:
  • Specific systematic reviews or meta-analyses on sinonasal malignancies, surgical outcomes of maxillectomy, and reconstructive techniques (e.g., from Head & Neck, Laryngoscope, Plastic and Reconstructive Surgery journals). Search PubMed using terms like "maxillectomy classification," "maxillary sinus cancer," "midface reconstruction."